ROIV in the 13F filings
Roivant Sciences LTD · CUSIP G76279101
- Quarter end
- 30 Sep 2025
- the date the book describes
- Filed
- 17 Feb 2026
- latest of these filings; the earliest 13 Nov 2025
- Managers listing it
- 11
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q2 2025 and Q3 2025; 9 listed it in both
- Shares listed
- 100,401,055
- combined, among listed positions
- Reported value
- $1.5bn
- combined, at the quarter end
Among the 95 comparable managers: 5 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing ROIV in Q3 2025
11 of 11 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 60,766,984 shares now+5,257,703
- Voloridge Investment Management LLCnew position · 2,281,123 shares now+2,281,123
- Winton Group Ltdexisting position · 543,333 shares now+335,269
- ExodusPoint Capital Management LPexisting position · 632,908 shares now+228,164
Reductions
- Viking Global Investors LPexisting position · 23,594,831 shares now-10,642,948
- Greenlight Capitalexisting position · 2,275,529 shares now-2,275,528
- Woodline Partners LPexisting position · 3,065,590 shares now-934,443
- Point72 Asset Management LPexisting position · 2,608,294 shares now-342,838
- PDT Partners LLCexisting position · 617,462 shares now-177,964
New positions and exits
New (1)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2021 | 1 | $889m | n.a. | n.a. |
| Q1 2022 | 1 | $436m | n.a. | n.a. |
| Q2 2022 | 1 | $359m | n.a. | n.a. |
| Q3 2022 | 2 | $292m | n.a. | n.a. |
| Q4 2022 | 3 | $829m | n.a. | n.a. |
| Q1 2023 | 6 | $715m | n.a. | n.a. |
| Q2 2023 | 8 | $1.0bn | n.a. | n.a. |
| Q3 2023 | 8 | $1.7bn | n.a. | n.a. |
| Q4 2023 | 6 | $1.5bn | 2 | 5 |
| Q1 2024 | 6 | $912m | 2 | 2 |
| Q2 2024 | 8 | $1.4bn | 5 | 3 |
| Q3 2024 | 8 | $1.4bn | 6 | 2 |
| Q4 2024 | 8 | $1.3bn | 4 | 3 |
| Q1 2025 | 7 | $1.1bn | 4 | 2 |
| Q2 2025 | 9 | $1.2bn | 5 | 3 |
| Q3 2025 | 11 | $1.5bn | 5 | 5 |
| Q4 2025 | 14 | $1.9bn | 16 | 15 |
| Q1 2026 | 14 | $3.3bn | 18 | 15 |
| Q2 2026 | 15 | $4.5bn | 20 | 11 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ROIV and LLY →ROIV and JNJ →ROIV and VRTX →Choose a stock to compare with ROIV →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ROIV, latest filings →Back to the 13F Explorer →